P2Y11 Antagonist B7508: Precision Inhibitor for GPCR Signaling in Immunology and Cancer Models

Executive Summary: The P2Y11 antagonist (B7508) is a chemically defined, water-soluble inhibitor of the P2Y11 G protein-coupled receptor (GPCR), supplied by APExBIO for research use only (product page). It demonstrates effective antagonism of P2Y11 signaling, a pathway central to inflammation and cellular migration processes (Liu et al., 2021). B7508 exhibits stability when stored at -20°C and is shipped on blue ice to maintain integrity. Its application has been validated in cellular assays examining breast cancer invasiveness, with data supporting its reversal of QPRT-induced cell migration and myosin light chain phosphorylation. The compound's well-documented performance and clear usage guidelines make it a gold standard for researchers dissecting GPCR-mediated signaling in immunology, oncology, and inflammation studies.

Biological Rationale

The P2Y11 receptor belongs to the purinergic P2Y family of G protein-coupled receptors, which respond to extracellular nucleotides. P2Y11 activation regulates key cellular processes, including calcium mobilization, immune cell activation, and cytokine release. Dysregulation of P2Y11 signaling has been implicated in inflammatory diseases and cancer progression, notably in mechanisms driving cell migration and metastasis (Liu et al., 2021). Targeting this receptor with selective antagonists enables precise interrogation of purinergic signaling in physiological and pathophysiological contexts. The sodium salt form of (Z)-N-(3,7-disulfonaphthalen-1-yl)-4-methyl-3-(((Z)-((2-methyl-5-((Z)-oxido((3-sulfo-7-sulfonatonaphthalen-1-yl)imino)methyl)phenyl)imino)oxidomethyl)amino)benzimidate (B7508) offers high specificity, supporting its use in mechanistic and translational research workflows.

Mechanism of Action of P2Y11 antagonist

B7508 exerts its effects by competitively antagonizing the P2Y11 receptor, a GPCR that primarily couples to G_s proteins. Upon binding, B7508 prevents the receptor's conformational activation by endogenous ligands such as ATP, thereby inhibiting downstream signaling events. This blockade results in reduced cAMP production, attenuated calcium mobilization, and suppression of related kinase cascades, including those modulating cytoskeletal dynamics and cell motility (related article).

Notably, in breast cancer models, P2Y11 antagonism impairs QPRT-induced myosin light chain phosphorylation, a process essential for enhanced cell migration and invasion. This mechanistic linkage positions the P2Y11 antagonist as a functional tool for dissecting purinergic and GPCR signaling (see P2Y11 Antagonist: Precision Tools, which this article extends by integrating peer-reviewed mechanistic data).

Evidence & Benchmarks

• B7508 reverses QPRT-induced invasiveness and myosin light chain phosphorylation in breast cancer cells (Liu et al., 2021, https://doi.org/10.3389/fendo.2020.621944).
• Demonstrates high water solubility (<19.74 mg/ml), supporting flexible dosing in aqueous assay systems (APExBIO product docs).
• Maintains chemical stability when stored at -20°C; solutions should be freshly prepared to preserve activity (APExBIO product docs).
• Validated as a robust cell signaling inhibitor in immunology and inflammation pathway models (aimmunity.net overview).
• Supplied as a beige solid, shipped on blue ice to maintain quality during transit (APExBIO).

Applications, Limits & Misconceptions

B7508 is primarily designed for basic and translational research, especially in the following domains:

• Immunology research: Enables study of P2Y11’s role in immune cell activation and cytokine release.
• Inflammation pathway modulation: Facilitates mechanistic studies into purinergic signaling and inflammatory mediator release.
• Cancer metastasis modeling: Demonstrates efficacy in reversing QPRT-driven invasion (Liu et al., 2021).
• Neuroinflammation studies: Offers potential in dissecting GPCR-mediated neuroimmune interactions (hypothesis, pending direct evidence).
• Autoimmune disease research: Serves as a tool for modulating purinergic signaling in immune dysregulation contexts (see also; this article provides updated mechanistic insights).

Common Pitfalls or Misconceptions

• Not for diagnostic or therapeutic use: B7508 is strictly for research; clinical applications are not validated (APExBIO).
• Instability in solution: Prolonged storage of aqueous solutions can result in reduced efficacy; use freshly prepared aliquots for each experiment.
• Limited selectivity beyond P2Y11: While highly specific, off-target effects at high concentrations cannot be fully excluded; recommended to titrate carefully.
• No effect in P2Y11-negative cells: Ineffective in models lacking functional P2Y11 expression.
• Chemical degradation above -20°C: Avoid repeated freeze-thaw cycles or storage above recommended temperature.

Workflow Integration & Parameters

B7508 is supplied as a beige solid with a molecular weight of 986.84 g/mol and the formula C₃₇H₂₆N₄Na₄O₁₅S₄. It dissolves readily in water up to 19.74 mg/ml. For optimal results, prepare solutions fresh prior to use and avoid long-term storage. Store the dry compound at -20°C. Shipping is conducted on blue ice to preserve stability (APExBIO product page).

Experimental designs using B7508 should include dose-response validation, especially when transitioning between cell types or assay platforms. For GPCR signaling assays, typical working concentrations range from 0.1 μM to 10 μM, but specific titration is advised. For guidance on assay configuration and troubleshooting, see this protocol-focused overview; the current article adds recent peer-reviewed benchmarks.

Conclusion & Outlook

The P2Y11 antagonist (B7508) from APExBIO is a rigorously defined, high-specificity tool for dissecting GPCR signaling pathways in immunology, inflammation, and cancer metastasis research. Its validated efficacy in reversing QPRT-driven cellular invasion and its favorable physicochemical properties distinguish it as a premier reagent for mechanistic and translational studies. Ongoing advances in purinergic signaling research may further expand its utility, particularly as models of neuroinflammation and autoimmune disease evolve. For comprehensive technical details, refer to the official P2Y11 antagonist product page.